| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000039416 |
| Receipt No. | R000044939 |
| Scientific Title | Effects of consumption of the proanthocianidins derived from Acacia Bark on blood pressure: a randomized, double-blind, placebo-controlled, parallel-group trial |
| Date of disclosure of the study information | 2020/02/06 |
| Last modified on | 2021/02/03 (Ver. 5) |
| Basic information | ||
| Public title | Effects of consumption of the test food on blood pressure | |
| Acronym | Effects of consumption of the test food on blood pressure | |
| Scientific Title | Effects of consumption of the proanthocianidins derived from Acacia Bark on blood pressure: a randomized, double-blind, placebo-controlled, parallel-group trial | |
| Scientific Title:Acronym | Effects of consumption of the proanthocianidins derived from Acacia Bark on blood pressure | |
| Region |
|
|
| Condition | |||
| Condition | Healthy Japanese subjects | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the effects of 12-week-consumption of the test food on improving blood circulation and blood pressure |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1. The measured value of sitting systolic blood pressure (SSBP) at 12 weeks after the start of test-food consumption (12w) |
| Key secondary outcomes | 1. The ratio of the number of subjects who are less than 130 mmHg in SSBP and no more than 89 mmHg in sitting diastolic blood pressure (SDBP) at 12w
2. The measured values of SSBP at eight weeks after the start of test-food consumption (8w) 3. The measured values of SSBP at four weeks after the start of test-food consumption (4w) 4. The measured values of SSBP at the examination before test-food consumption (0w) 5. The change values of SSBP between at 0w and at 4w, 8w and 12w 6. The measured values of SDBP at 0w, 4w, 8w and 12w 7. The change values of SDBP between at 0w and at 4w, 8w and 12w 8. The measured value of superoxide dismutase (SOD) before cold water load and 30 min after cold water load at 0w, and the measured difference value* of SOD between before and 30 min after cold water load at 0w 9. The measured values of SOD before and 30 min after cold water load at 12w, and the measured difference value* of SOD between before and 30 min after cold water load at 12w 10. The change values of SOD before and 30 min after cold water load between at 0w and 12w, and the change difference value* of SOD between before and 30 min after cold water load between at 0w and 12w 11. The measured values of blood flow before and 30 min after cold water load at 0w and the measured difference value* of blood flow between before and 30 min after cold water load at 0w 12. The measured and change values of blood flow before and 30 min after cold water load at 12w and the measured difference value* of blood flow between before and 30 min after cold water load at 12w 13. The change values of blood flow before and 30 min after cold water load between at 0w and 12w and the measured difference value* of blood flow between before and 30 min after cold water load between at 0w and 12w *8-13 difference value = the value of blood flow at 30 min after cold water load - the value of blood flow before cold water load |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | YES |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | Central registration |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 12 weeks
Test food: Tablet containing proanthocianidins derived from Acacia Bark Administration: 1. During test-food consumption: Take six tablets with water without chewing before meals. * If you forget to take the test food, take it as soon as you remember within the day. 2. At the examination before test-food consumption: Take six tablets with water without chewing 60 minutes before cold water load. |
|
| Interventions/Control_2 | Duration: 12 weeks
Test food: Placebo tablet Administration: 1. During test-food consumption: Take six tablets with water without chewing before meals. * If you forget to take the test food, take it as soon as you remember within the day. 2. At the examination before test-food consumption: Take six tablets with water without chewing 60 minutes before cold water load. |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy Japanese adult subjects
2. Subjects who have relatively high levels of blood pressure, or being anxious about or suffering their blood pressure 3. Subjects who are judged as eligible to participate in the study by the physician 4. Subjects who are no more than 89 mmHg in diastolic blood pressure at screening (before test-food consumption) 5. Subjects who are between 130 mmHg or more and 139 mmHg or less in systolic blood pressure at screening (before test-food consumption) |
|||
| Key exclusion criteria | 1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction
2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who have severe anemia 5. Subjects who have or are suspected of secondary hypertension 6. Subjects who drink alcoholic beverages or smoke cigars immoderately 7. Subjects who work late-night shift or are irregular of their life-styles 8. Subjects who have vigorous exercise habits 9. Subjects who use or take "Foods for Specified Health Uses", "Foods with Functional Claims", or other functional food/beverage in daily 10. Currently taking medicines (include herbal medicines) and supplements 11. Subjects who are allergic to medicines and/or the test food related products 12. Subjects who are pregnant, breast-feeding, and planning to become pregnant 13. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial or plan to participate another trial during this trial 14. Subjects who are judged as ineligible to participate in the study by the physician |
|||
| Target sample size | 60 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | ORTHOMEDICO Inc. | ||||||
| Division name | CEO | ||||||
| Zip code | 112-0002 | ||||||
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. | ||||||
| TEL | 03-3818-0610 | ||||||
| kazu@orthomedico.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | ORTHOMEDICO Inc. | ||||||
| Division name | R&D Department | ||||||
| Zip code | 112-0002 | ||||||
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan. | ||||||
| TEL | 03-3818-0610 | ||||||
| Homepage URL | |||||||
| nao@orthomedico.jp | |||||||
| Sponsor | |
| Institute | ORTHOMEDICO Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Acacia-No-Ki Co.,Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Medical Corporation Seishinkai, Takara Clinic |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | the ethical committee of the Takara Clinic, Medical Corporation Seishinkai |
| Address | 9F Taisei Building, 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan. |
| Tel | 03-5793-3623 |
| info@takara-clinic.com | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 66 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044939 |